[Click eStock] Genome and Company Holds Multiple Events Driving Corporate Value Increase This Year

[Asia Economy Reporter Hyunseok Yoo] Korea Investment & Securities analyzed on the 8th that Genome & Company holds multiple events this year that could increase its corporate value. No investment opinion or target price was provided.

Korea Investment & Securities assessed that Genome & Company's pipeline expansion is imminent. Jinhung Kook, a researcher at Korea Investment & Securities, said, "Genome & Company is developing a First-in-Class immuno-oncology drug based on newly discovered targets," adding, "They plan to present research results at the American Association for Cancer Research (AACR) conference scheduled for April."

He stated, "In February, they signed a joint research agreement with Swiss pharmaceutical company Debiopharm for new antibody target candidate substances," explaining, "Through multiple antibody new target candidates developed by Genome & Company and various ADC combination clinical trials held by Debiopharm, they plan to discover clinical development candidates optimized for ADC technology."

He particularly expected that various events in the first half of this year could lead to a rebound in Genome & Company's stock price. He said, "Genome & Company's stock price fell to around 50,000 KRW due to stock market adjustments but is currently seeking a rebound in the 60,000 KRW range," adding, "Meaningful momentum that can drive corporate value growth includes the expansion of indications to gastric cancer in the first half of this year and the announcement of new cancer target research results at AACR."

He emphasized, "In the second half of the year, entry into Phase 1b clinical trials for combination therapy with immuno-oncology drugs and Phase 1 clinical trials for autism by subsidiary Scioto are scheduled," adding, "As it is becoming one of the world's leading microbiome therapeutic companies, a valuation premium compared to domestic microbiome companies is justified."

This content was produced with the assistance of AI translation services.